AMSBIO has expanded its range of primary human cancer cells sourced from a wide variety of tissue types that allow the study of cancer in a more in vivo like fashion.Many scientists acknowledge that using immortalized cell lines as surrogates offers only a poor reflection of the diverse profiles of real cancer tumors. During long-term culture, immortalized cells adapt to their <I style="mso-bidi-font-style: normal">in vitro environment, and often mask or lose the in vivo phenotypic events being studied – in addition to hiding key epigenetic or immunotherapy markers. These shortfalls…
The deadline for compliance with the EU Medical Device Regulations is looming. On the 25th of May 2017, new EU regulations for medical devices and in vitro diagnostic medical devices entered into force, giving medical device companies a 3 / 5 - year transition period to achieve compliance. Whilst the MDR has been delayed as a result of the COVID-19 pandemic, by May 2021 medical devices must adhere to the updated regulations, transitioning from the Medical Device Directive (MDD) to the Medical Device Regulations (MDR). The implementation of the In Vitro Diagnostic Regulations (IVDR) follows…
UPPSALA, Sweden, February 2, 2021 - LINK Medical, the Northern European clinical research organization (CRO), and the Swedish women’s health company Gedea Biotech announced today that it has enrolled the first patient in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study is designed to confirm safety and efficacy of pHyph and is coordinated by Nottingham University NHS Hospitals Trust in the UK and LINK Medical.
Bacterial vaginosis is a vaginal infection with a…
27 January 2021
tranScrip is delighted to announce a significant minority investment from Palatine Private Equity Impact Fund, which complements the existing investment of tranScrip’s own Partners. The deal is a landmark for tranScrip, underpinning its growth as a leading specialist service provider.
tranScrip’s unique, highly skilled teams combine in-depth pharmaceutical expertise and functional competencies which allow them to lead and deliver successful development, registration and launch of new medicines across multiple therapeutic areas, including oncology, infectious diseases,…
Cambridge, UK – January 26 2021 – The cost of library preparation is one of the biggest obstacles to large next-generation sequencing (NGS) studies, slowing down the pace of insights from infectious disease surveillance, cancer research and beyond. At the Festival of Genomics, SPT Labtech announced an initiative with Thermo Fisher Scientific to co-market solutions that will enable variant detection at a fraction of the cost.
Sensitive variant detection can now be achieved at one-tenth of the library prep cost through miniaturization with the SPT Labtech mosquito HV genomics and SPT…
ProductLife Group already has a fairly long success story: born in 1993, focusing on RA since 2006 and after becoming a Group, through acquisitions from 2012 onwards, PLG was reborn once again after LBO by 21Invest.
All along, it has kept the ProductLife vision of contributing to improve human health, with its main competences, regulatory affairs, safety & vigilances and quality compliance.
In 2020, ProductLife Group has reached a first step of notoriety as PLG, a European leading service provider for top pharmaceutical companies.
Those strengths, this recognition, should be kept for the…
Saffron Walden, UK, 21st January 2021 / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to welcome David Cronk, CBiol, MRSB, to the team as its new Chief of Staff. The Company has also promoted long standing team member and previous Head of Chemistry, Dr Ray Boffey, to Executive Director of Medicines Research. Following a successful period of growth and expansion of its research team, both David and Ray bring a wealth of drug discovery experience and will further support Domainex’s ongoing growth plans.
David Cronk has over 30 years’ drug discovery…
The cfPure® Cell Free DNA Extraction Kit from AMSBIO is a magnetic bead-based DNA extraction kit designed to isolate circulating cell free DNA (cfDNA) from human plasma or serum samples.Using a quick, simple, and automation friendly protocol the kit allows users to quickly extract high quality cfDNA that is ready for use in downstream applications including next-generation sequencing, Bisulfite Sequencing, PCR, qPCR, ddPCR and other demanding applications. This optimized protocol gives highly reproducible results and higher yields relative to other magnetic bead-based methods.…
Research Triangle Park, NC, USA and Cambridge, UK, 20 January 2021 – Inivata, a leader in liquid biopsy, today announces that the first patients have been tested using InVisionFirst®-Lung as part of the Phase II ALKALINE trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC). As part of the study Inivata’s InVisionFirst-Lung liquid biopsy will be used to test and monitor ALK positive non-small cell lung cancer (NSCLC) patients initiating treatment with lorlatinib, Pfizer Inc.’s third generation ALK inhibitor therapy.
The aim of this academic trial, announced…
Cambridge and London, UK, 18 January 2021:
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.
The collaboration is focused on the discovery of novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis, and has now…